NOTE

🌱 created from: nigro_protocol

pretreatment_considerations_of_nigro_protocol

  • Emesis risk
    • LOW on all days.
  • Prophylaxis for infusion reactions
    • Routine prophylaxis is not indicated.
  • Vesicant/irritant properties
    • Mitomycin is a potent vesicant and can cause ulceration, necrosis, cellulitis, and tissue sloughing; avoid extravasation.[3] FU is an irritant but can cause significant tissue damage with a large volume, concentrated extravasation; avoid extravasation.[4]
  • Infection prophylaxis
    • Primary prophylaxis with G-CSF not indicated; use of G-CSF should be avoided in patients receiving concomitant chemoradiotherapy.
  • Dose adjustment for baseline liver or kidney dysfunction
    • Lower initial doses of mitomycin may be needed in patients with kidney insufficiency. Do not use mitomycin if serum creatinine >1.7 mg/dL.[3] A lower starting dose of FU may be needed for patients with liver impairment.

Treatment of anal cancer - UpToDate